Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06340360 · ClinicalTrials.gov registry record · Phase 2
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)
A Phase 2 study of Alopecia Areata, sponsored by Nektar Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 94
- Enrollment target
- 20
- Study locations
NCT06340360: Active Phase 2 study of Alopecia Areata, sponsored by Nektar Therapeutics.
NCT06340360 is a Phase 2 study of Alopecia Areata that is active but no longer recruiting, run by Nektar Therapeutics. The registered enrollment target is 94 participants, below the 1,952-participant average among 26 other Alopecia Areata trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06340360, a Phase 2 study of Alopecia Areata, is active but no longer recruiting, sponsored by Nektar Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 94 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an interventional, randomized, double blind, parallel group, placebo-controlled, Phase 2b, 3-arm study to assess the effect of pegylated-recombinant-human interleukin-2 (rezpegaldesleukin) in adult participants with severe to very severe alopecia areata. The estimated duration includes a screening period of up to 35 days, a 36-week treatment period, an optional 16-week treatment extension period, and a 24-week follow-up period. The maximum study duration is approximately 81 weeks for all participants.
Primary Outcome
The SALT score is the sum of percentage of hair loss in all areas with a maximum score of 100 (higher score indicates greater hair loss).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Rezpegaldesleukin
Study Locations (20)
Ontario
- Nektar Investigative Site - Markham
- Nektar Investigative Site - Oakville
- Nektar Investigative Site - Richmond Hill
Lower Silesian Voivodeship
- Nektar Investigative Site - Wroclaw
- Nektar Investigative Site - Wroclaw
- Nektar Investigative Site - Wroclaw
Texas
- Nektar Investigative Site - Frisco
- Nektar Investigative Site - Pflugerville
California
- Nektar Investigative Site - Northridge
Georgia
- Nektar Investigative Site - Atlanta
Illinois
- Nektar Investigative Site - Gurnee
Indiana
- Nektar Investigative Site - Indianapolis
Michigan
- Nektar Investigative Site - Clinton Township
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2024-04-02 |
| Est. Completion | 2026-08 |
| Phase | Phase 2 |
What the registry record for NCT06340360 still lists
NCT06340360 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 94 participants, a relatively small participant target, below the 1,952-participant average among 26 other Alopecia Areata trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Alopecia Areata appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06340360 names 20 study sites across 15 states, led by Ontario, Lower Silesian Voivodeship, Texas.
Frequently Asked Questions
What is clinical trial NCT06340360 about?
NCT06340360 is a clinical study titled "A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)". This is an interventional, randomized, double blind, parallel group, placebo-controlled, Phase 2b, 3-arm study to assess the effect of pegylated-recombinant-human interleukin-2 (rezpegaldesleukin) in adult participants with severe to very severe alopecia areata. The estimated duration includes a sc...
What is the current status of trial NCT06340360?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 94 participants. The study started on 2024-04-02. Estimated completion is 2026-08.
What conditions does trial NCT06340360 study?
This clinical trial studies the following conditions: Alopecia Areata.
What interventions are being tested in trial NCT06340360?
The interventions under investigation include: Placebo (DRUG), Rezpegaldesleukin (DRUG).
Who is sponsoring clinical trial NCT06340360?
This trial is sponsored by Nektar Therapeutics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06340360 being conducted?
This trial has 20 study locations across California, Georgia, Illinois, Indiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alopecia Areata
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06340360's enrollment target sits among peer trials
94 14th of 26 higher than 13 of 26 other Alopecia Areata trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alopecia Areata trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata
RECRUITING · Phase 2
-
A Study of LAD603 in Adults With Alopecia Areata
RECRUITING · Phase 2
-
Dupilumab in the Treatment of Pediatric Alopecia Areata
RECRUITING · Phase 2
-
Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
RECRUITING · Phase 2
-
Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome
RECRUITING · Phase 2
-
Regeneron AA Multicenter (Dupilumab)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03747146 · 94 participants · NA
Enhanced Recovery After Surgery (ERAS) Total Knee Replacement (TKR) With a Transitional Pain Service
- NCT04061421 · 94 participants · Phase 1
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
- NCT04205968 · 94 participants · Phase 2
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
- NCT04464759 · 94 participants · Phase 1
A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI